Abstract: A method and system provides for determining position information for tracking tags relative to a plurality of tracking stations. The method and system includes initiating a wake cycle at a first time including pausing for a first time period and thereafter emitting a blast of light in a light sweep. The method and system includes the tracking tags waking at the first time and activating a photoreceptor embedded therein. The tracking tags detecting the blast of light and initiating a tracking timer therein. From there, the method and system includes the tracking stations emitting a vertical laser in a circular rotation at a rotational speed. Whereby, the tracking tags detect the vertical laser at a timestamp and detect an angle between the tracking tag tracking stations based thereon.

Abstract: A system for identifying a location of one or more assets in a predefined two-dimensional area comprises at least three tracking stations and one or more tracking tags. Each tracking station selectively emits a vertical laser line upon which is embedded a unique identifier, selectively sweeps its laser line about its central axis such that each tracking station's laser line sweeps across at least a portion of the predefined 2-D area, and selectively transmits a current angle of its laser line as its laser line sweeps about its central axis. Each tracking tag detects a laser line from at least three tracking stations within its line of sight. Each tracking tag decodes the unique tracking station identifier, receives the current angle from the tracking station corresponding to the detected laser line, and stores the decoded unique tracking station identifier and the received current angle.

Abstract: The present disclosure relates to dosing regimens for treating cancer by administering epacadostat in combination with an antibody, or an antibody fragment thereof, that binds to PD-1.

Abstract: A system for identifying a location of one or more assets in a predefined two-dimensional area comprises at least three tracking stations and one or more tracking tags. Each tracking station selectively emits a vertical laser line upon which is embedded a unique identifier, selectively sweeps its laser line about its central axis such that each tracking station's laser line sweeps across at least a portion of the predefined 2-D area, and selectively transmits a current angle of its laser line as its laser line sweeps about its central axis. Each tracking tag detects a laser line from at least three tracking stations within its line of sight. Each tracking tag decodes the unique tracking station identifier, receives the current angle from the tracking station corresponding to the detected laser line, and stores the decoded unique tracking station identifier and the received current angle.

Abstract: The present invention is directed to pharmaceutical methods for the treatment of CD30 positive diseases, such as Hodgkin's disease, by administration of a combination of at least one sheddase inhibitor and at least one anti-CD30 immunotherapeutic.

Abstract: The present invention is directed to pharmaceutical methods for the treatment of CD30 positive diseases, such as Hodgkin's disease, by administration of a combination of at least one sheddase inhibitor and at least one anti-CD30 immunotherapeutic.

Abstract: This invention concerns the use of synthetic Lipid A analog P9132 to activate human monocytes, and inhibit growth of tumor cells.